SCHEDULE: Vanguard Group Exits Mirum Pharma Stake

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Mirum Pharmaceuticals Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for Mirum Pharmaceuticals Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares of Mirum Pharmaceuticals Inc., representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It primarily reflects an internal administrative change for The Vanguard Group regarding how its beneficial ownership is reported, rather than a direct positive or negative assessment of Mirum Pharmaceuticals Inc.

Positives

• The filing provides transparency regarding The Vanguard Group's current beneficial ownership status in Mirum Pharmaceuticals Inc.
• The change primarily reflects an internal operational realignment within Vanguard, rather than a direct negative assessment of Mirum Pharmaceuticals Inc.'s performance.

Negatives

• The Vanguard Group, as the primary reporting entity, no longer reports a beneficial ownership stake in Mirum Pharmaceuticals Inc.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Mirum Pharmaceuticals Inc. or The Vanguard Group's future investment intentions, beyond the structural change in reporting.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

Industry Context

StockSavvy.ai notes that institutional investors like The Vanguard Group frequently undergo internal reorganizations or adjustments to their reporting structures. This filing primarily reflects an internal operational change for Vanguard rather than a direct statement on Mirum Pharmaceuticals Inc.'s performance or prospects. Such disaggregated reporting is a common practice for large asset managers to comply with SEC regulations.

Stakeholder Impact

• Shareholders: Existing shareholders of Mirum Pharmaceuticals Inc. should be aware that The Vanguard Group, as a single entity, no longer reports a beneficial ownership stake, though other Vanguard entities may still hold shares.
• Investment Professionals: Provides clarity on The Vanguard Group's reporting structure for beneficial ownership.

Next Steps

• Mirum Pharmaceuticals Inc. will continue to be monitored for any future ownership filings from Vanguard's disaggregated entities.

Key Dates

Keywords

Vanguard Group, Mirum Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Investment Adviser, Realignment